Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HLX48

Phase 1Small molecule

Shanghai Henlius Biotech

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced/metastatic Solid TumorsRecruiting

Advanced/metastatic Solid TumorsPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Advanced/metastatic Solid Tumors

NCT07473726

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX48 (EGFR/c-MET Bispecific Antibody-Drug Conjugate) in Participants With Advanced/Metastatic Solid Tumors

Recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 1·NCT07473726·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HLX48. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HLX48 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HLX48. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Henlius Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Shanghai Henlius Biotech

Related News